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Chronic myelomonocytic leukemia (CMML) is a rare
clonal hematologic malignancy of the elderly (median age
70), with an incidence of 1 in 100,000/year. CMML is char-
acterized by persistent blood monocytosis, which combines
myelodysplastic and myeloproliferative features, and is
currently classiﬁed by the World Health Organization into a
group of myelodysplastic/myeloproliferative disorders.
Virtually all patients have somatic mutations, especially in
TET2, SRSF2, and ASXL1 genes, and about 30% of the patients
progress to acute myeloblastic leukemia (AML). Median
survival is around 3 years [1]. Recent prognostic systems
have been published for CMML, stressing the poor prognosis
of excess of marrow blasts, RBC transfused anemia, prolif-
erative features abnormal karyotype, and, recently, ASXL1 or
Cas-Br-Murine ecotropic retroviral transforming sequence
(CBL) mutations [1,2].
In patients who are not candidates for allogeneic he-
matopoietic stem cell transplantation (HSCT), especially due
to age, treatment for CMML still relies on hydroxyurea in
proliferative form, but with limited effect [3]. Poor response
to intensive chemotherapy (IC) has been reported, in
particular by our group [4]. Recent more encouraging results
have been observed with hypomethylating agents (HMAs) in
retrospective studies, both with azacitidine and decitabine
[5], with overall response rates ranging from 20% to 45%,
including 10% to 20% complete remission, and median sur-
vival of about 2 years from treatment initiation. However,
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1083-8791/ 2016 American Society for Blood andMarrow Transplantation.results were often difﬁcult to interpret because of patient
heterogeneity. In a Groupe Francophone des Myélodys-
plasies prospective study in 39 patients with advanced
CMML with a median of 10% marrow blasts, Braun et al. [6]
observed a response rate of 38% and a 2-year overall sur-
vival rate of 48%. Azacitidine was approved in the European
Union for CMML patients withmarrow blasts> 10% andWBC
counts< 13 G/l, based on the few CMML patients included in
the prospective AZA001 study [7].
As inmyelodysplastic syndrome, allogeneic HSCT remains
the only potentially curative treatment of CMML, but only
one third of patients are alive and free of disease several
years after transplantation, with death due to (in about the
same proportion) transplant-related mortality or disease
progression. Main pretransplant risk factors for post-
transplant outcomes in CMML include disease status, cyto-
genetic ﬁndings, and comorbidities [8-10].
The report by Kongtim et al. [11] in this issue of Biology in
Blood and Marrow Transplantation is an interesting contribu-
tion. In addition to being a relatively important series of HSCT
in CMML (83 patients transplanted between 1991 and 2013), it
suggests for theﬁrst time that pretransplant treatmentwith at
least 3 cycles of HMAs may have improved CMML outcome,
essentially by signiﬁcantly reducing the relapse risk (from 35%
to 22%), with no impact on transplant-related mortality. The
lower risk of relapse translated into signiﬁcantly better
progression-free survival (43%versus27%)butnot signiﬁcantly
better overall survival. Other ﬁndings favorably impacting
disease-free survival were pretransplant marrow blast < 5%,
the use of a matched related donor rather than an unrelated
donor, and theoccurrenceof chronic graft-versus-hostdisease.
On the other hand, the occurrence of acute graft-versus-host
disease was deleterious, whereas, interestingly, unfavorable
karyotype had no prognostic inﬂuence on outcome.
The role of treatment before HSCT (IC, or, more recently,
HMAs) has been a matter of debate in MDS over the last
2 decades. Several cooperative groups, in particular the
Groupe Francophone des Myélodysplasies (unpublished re-
sults) and the European Group for Blood and Marrow Trans-
plantation (De Witte, personal communication), launched
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patients could be included) to ﬁrst-line HSCTor IC followed by
HSCT. However, those trials failed to accrue more than a few
patients, possibly because clinicians were concerned about
the risk of disease progression before transplantation in the
absence of rapid initiation of IC or, conversely, by the potential
toxicity of IC in patients ready for transplantation.
We therefore have to rely on retrospective studies that
included amajorityofMDSpatients (and relatively fewCMML
patients), which generally concluded that pretransplant
chemotherapy was not associated with an overall beneﬁt but
that patients who reached complete remission before trans-
plant had an improved outcome [12,13]. The French HSCT
group (SFGM-TC) reported that the use of IC or HMAs pre-
transplant was associated with similar post-transplant out-
comes inMDS [12],whereas in a second study they found that
HMAs pretransplant showed no beneﬁt over immediate
transplant (neither of those series studied CMML patients)
[14]. Symeonidis et al. [10], on behalf of the European Group
for Blood and Marrow Transplantation, reported the largest
series of transplanted CMML patients (n ¼ 513). Response to
treatment before transplant was the major prognostic factor
for post-transplant outcome, but the authors provided no
details for each treatment. In a prospective study in higher
risk MDS that compared patients with and without a donor,
we found that the use of HMAs before transplant had no
signiﬁcant impact on transplant outcome, but most pa-
tients(76%) had received an HMA, and the administration of
HMAs was not randomized [15]. Because prospective trials
randomizing patients with a donor between immediate
transplant and treatment (IC or HMAs) followed by HSCT do
not appear to be feasible, recommendations are often based
on expert opinion, which often suggest treatment before
HSCT when marrow blasts are greater than 10% [16].
Because Kongtim et al. [11] focus on CMML, a different
outcome with HSCT compared to MDS may have occured, in
particular because of their frequent proliferative component.
However, this study also suffers from its retrospective nature.
First, the study population included CMML cases that were
actually transplanted and not all potential candidates for
transplant, some of whom may not have proceeded to
transplant, in particular because they had a high marrow
blast percentage before transplant. In our experience and
that of other groups, one third of MDS/CMML transplant
candidates are eventually not transplanted because of dis-
ease progression or complications occurring before the
scheduled transplant [15]. In Kongtim et al. [11], the fact that
themedian pretransplantmarrow blast percentagewas 4% in
the HMA-treated group (ie, <5% in at least 50% of the pa-
tients) and that 41% of patients had reached complete
remission or marrow complete remission with HMAs also
support the assumption that patient selection occurred,
because HMAs generally do not yield such proportions of
complete remission/marrow complete remission. In addi-
tion, in Kongtim et al.’s study, the patient population was
quite heterogeneous, and although 36 had progressed to
AML, 40 had CMML-1, a subgroup of CMML that may not
always require transplant in the absence of additional poor
prognostic factors. Also of note is that patients who had
progressed to AML tended to have received IC more often
and HMAs less often than CMML-1/2 patients. Finally, almost
all patients had received IC or HMAs, and comparison with
patients receiving upfront HSCT was not possible.
Prospective randomized studies testing the role of pre-
transplant treatment (with IC or HMAs) would certainly beuseful in CMML, but they would be even less feasible than in
MDS, given the disease rarity. Thus, Kongtim et al.’s results
suggesting thatHMAsmaybe useful in CMMLpatients, before
HSCT, and may be more effective than IC are interesting,
although they must be interpreted with caution. They are in
agreement with the known limited value of IC in CMML pa-
tients, whether or not those patients progressed to AML. They
should be conﬁrmed, however, in prospective observational
studies including all CMML patients who are candidates for
HSCT (relying on available prognostic scoring systems) and
comparingdonor andnodonor outcomes. In the latter patient
group, outcomebasedonpretreatment approaches, including
IC,HMAs, or no treatment,would also be analyzed. The SFGM-
TC and Groupe Francophone des Myélodysplasies are
currently about to begin such a study in France.
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